ClinicalTrials.Veeva

Menu

Rapid Treatment of Shock Without Trauma (SWOT)

ZOLL Medical logo

ZOLL Medical

Status

Completed

Conditions

Shock

Treatments

Device: Full SWOT Model

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

Evaluate the implementation of a standardized mobile resuscitation model to manage SWOT within a large acute care hospital setting.

Full description

Immediately upon identification of SWOT, the SWOT Team will be activated by clinicians to respond to the patient bedside. Clinicians on-site will initiate patient care as directed by hospital protocol. Upon arrival, the SWOT Team will take over the management of patient care. The team will include 1-2 intensivists and multiple clinicians with clearly defined roles, dependent upon clinical presentation. The mobile resuscitative platform equipped with critical care technology will be delivered to the bedside (refer to appendix for full equipment content).

The SWOT Team will implement goal-directed therapy using real-time monitoring and advanced diagnostic point-of-care tools. ultrasound, arterial and central lines will be placed by the intensivist(s) to monitor the physiology of the patient during treatment in real-time. Other team members (RNs, Respiratory Therapist's, residents, anesthesiologists, and technicians) will place the patient on continuous ECG and SPO2 monitoring, continuous capnographic monitoring via nasal canula or Endotracheal tube, and continuous cerebral and regional NIRS monitors. Point-of-care laboratory values will also be measured. Resuscitative interventions will be performed as directed by team leader to target the following physiological target parameters:

  • SpO2 > 85%
  • PaO2 > 50 mmHg
  • NIRS > 65%
  • Lactate normal or trending down
  • EtCO2 >20 mmHg
  • Mean Arterial Pressure > 65 mmHg
  • SVO2 > 60%

Enrollment

27 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18 to 75 years of age (inclusive)

  2. Presence of shock, defined as systolic blood pressure (SBP) less than 90 mmHg with signs of hypoperfusion, including at least one of the following (without alternate causes):

    • low cardiac index (<2.2 L/min/m2)
    • elevated filling pressures of the left heart (pulmonary capillary wedge pressure [PCWP] >15 mmHg) and/or
    • right heart (central venous pressure [CVP] >10 mmHg)
    • non-perfusing cardiac rhythm or cardiac arrest
    • mixed venous oxygen saturation <60% or >80% without non-shock cause
    • Heart rate >90 beats per minute
    • Respiratory rate >20 breaths per minute
    • White blood cell count >12 or < 4
    • Temperature >38°C or <35°C
    • SOFA score ≥2 with vasopressor requirement and elevated lactate >2 mmol/L (>18 mg/dL) despite adequate fluid resuscitation
    • Central venous pressure <8 mmHg
    • Obstruction such as pulmonary embolus on imaging
  3. Admitted to Abbott Northwestern

  4. Rapid Response Team call or request

  5. Patients who previously agreed to allow their medical record information to be used for Allina Health research (i.e. Minnesota Research Authorization (MRA) "Yes") or those who have not explicitly declined use of their medical information in Allina Health research (i.e. MRA "Null")

Candidates for the prospective case series must meet the following inclusion criterion:

  1. Interventional assessment and treatment by SWOT Team (full-implementation period only)
  2. Patients who previously agreed to allow their medical record information to be used for Allina Health research (i.e. Minnesota Research Authorization (MRA) "Yes") or those who have not explicitly declined use of their medical information in Allina Health research (i.e. MRA "Null")

Exclusion criteria

  1. Known or suspected pregnancy
  2. Significant trauma
  3. BMI > 50 kg/m2
  4. Pre-existing Do Not Resuscitate order
  5. Presence of orders limiting resuscitation efforts during the initial resuscitative period (less than 2 hours from the onset of protocol)
  6. Refusal to receive whole blood or blood products
  7. Severe brain injury (anoxic, traumatic, hemorrhagic or ischemic)
  8. presence of an assist device such as intra-aortic balloon pump
  9. Advanced chronic organ dysfunction
  10. Known or presumed COVID-19
  11. Patients with a status of MRA "No"
  12. Patient in ICU at time of shock

Candidates for the prospective case series will be excluded if the following condition is present:

  1. Patients with a status of MRA "No"
  2. Patient in ICU at time of shock

Trial design

27 participants in 1 patient group

Full-implementation
Description:
Patients experiencing shock without trauma once all training is in place and devices are deployed
Treatment:
Device: Full SWOT Model

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems